Hummingbird closes extended $25M Series B round led by SK Holdings
Category: #headline  By Akshay Kedari  Date: 2020-05-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Hummingbird closes extended $25M Series B round led by SK Holdings

Hummingbird Bioscience, a biotherapeutics company, has reportedly closed an extended $25 million Series B funding. The company focuses on the development and discovery of breakthrough therapies. This fund-raising event brings the total capital raised by the company to date via strategic partnerships and financing activities to more than $65 million.

The new investor, SK Holdings, has contributed to the extension of the Series B round, alongside existing shareholders such as Heritas Capital & SEEDS Capital, which is Enterprise Singapore’s investment arm. The Series B funding was recently extended to $25 million owing to a significant over-subscription, through the addition of the value-added and quality investors. The company is planning to adopt the new funds to surge new candidates’ development as well as strengthen the scientific and R&D capabilities.

According to Dr. Piers Ingram, Hummingbird Bioscience’s co-founder and Chief Executive Officer, the company is excited to welcome SK Holdings as their new investor. Dr. Ingram has stated that the company is focusing on assisting and benefitting patients suffering from a wide range of diseases by developing a robust portfolio of new therapies. The recent fund-raising event delivers additional resources to the company to create early-stage pipeline as well as aid the clinical development of the lead programs.

Chik Wai Chiew, Heritas Capital Management’s Chief Executive Officer and Executive Director, has commented that the company has been continuously assisting Hummingbird and its team since the company’s Series A extended round. It prioritizes helping the leading biotech companies such as Hummingbird to significantly develop treatments and address the needs of patients, even during the slowdown of investments due to the coronavirus pandemic.

Hummingbird had previously announced the positive data published on the HMBD-001, its lead candidate and first-in-class HER3 antibody as well as the manufacturing of its first-in-class VISTA antibody, HMBD-002, earlier this year. The Phase 1 trials of these candidates will be initiated following the regulatory submissions, which is expected in the 2nd half of 2020.

Source credit:

https://www.hummingbirdbioscience.com/en/news-events/hummingbird-bioscience-series-b-extension/ 

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Oscar Parodi becomes 1st UK infant to be treated with a Cannabis drug
Oscar Parodi becomes 1st UK infant to be treated with a Cannabis drug
By Akshay Kedari

The cannabis based drug has previously been used for epilepsy treatment and this study is being co...

Outcomes of dog cancer clinical trial increase hopes for human use
Outcomes of dog cancer clinical trial increase hopes for human use
By Akshay Kedari

Selvax Pty Ltd, the Australian cancer immunology group engaged in developing immunology based treatm...

KYB inks deal with REE Automotive to bring advanced EV solutions
KYB inks deal with REE Automotive to bring advanced EV solutions
By Akshay Kedari

  KYB’s highly advanced semi-active and active system solutions will drive the next-ge...